세계의 폐암 치료제 시장 - 산업 규모, 점유율, 동향, 기회, 예측, 암세포 유형별(비소세포폐암, 소세포폐암), 치료별, 지역별, 경쟁별(2020-2030년)

Lung Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Cell Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer ), By Treatment, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,292,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,691,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,187,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

폐암 치료제 세계 시장 규모는 2024년 254억 3,000만 달러로 평가되었고, 예측 기간 중 CAGR은 9.62%를 나타내고, 2030년에는 405억 5,000만 달러에 달할 것으로 예측됩니다.

세계의 폐암 치료제 시장은 인지도 향상, 조기 진단, 표적 요법 및 면역 요법의 진보에 의해 강력한 성장을 이루고 있습니다. 폐암은 전 세계적으로 가장 흔하게 진단되고 치명적인 형태의 암 중 하나로 남아 있어 의료 시스템에서 효과적인 치료가 최우선 과제입니다. 흡연율의 상승, 환경오염물질에의 노출, 인구의 고령화는 혁신적인 치료 옵션에 대한 수요를 부추기는 주요 요인입니다. 비소세포폐암은 가장 흔한 유형이며, 특히 유전자 돌연변이에 초점을 맞춘 표적 치료를 통해 가장 큰 치료적 발전을 이루었습니다. 면역요법도 기세를 늘리고 있어 신체의 면역계가 암세포를 인식해, 보다 효과적으로 공격하는 것을 돕는 것으로 희망을 가져오고 있습니다. 세계보건기구(WHO)는 담배를 중대한 건강 리스크로 인식하고 있으며, 특히 저·중소득국에서 매년 800만명 이상의 사망자를 내고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	254억 3,000만 달러
시장 규모 : 2030년	405억 5,000만 달러
CAGR 2025-2030년	9.62%
급성장 부문	면역요법
최대 시장	북미

시장 성장 촉진요인

폐암 이환율 상승

주요 시장 과제

높은 치료비

주요 시장 동향

맞춤형 의료로 이동

목차

제1장 개요

• 시장의 정의
• 시장 범위
  • 대상 시장
  • 조사 대상 연도
  • 주요 시장 세분화

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계의 폐암 치료제 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 암세포 유형별(비소세포폐암(NSCLC), 소세포폐암(SCLC))
  • 치료별(화학요법, 방사선요법, 면역요법, 표적요법, 기타 치료)
  • 지역별
  • 기업별(2022년)
• 시장 맵
  • 암세포 유형별
  • 치료별

제6장 북미의 폐암 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 폐암 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 폐암 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주

제9장 남미의 폐암 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 폐암 치료제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 아랍에미리트(UAE)
  • 사우디아라비아
  • 남아프리카

제11장 시장 역학

• 성장 촉진요인
  • 폐암의 이환율 증가.
  • 흡연자 수 증가
  • 면역요법 수요 증가
• 과제
  • 고액의 암 치료
  • 약의 부작용
  • 숙련노동력 부족

제12장 시장 동향과 발전

• 제품 출시
• 합병과 인수
• 기술적 진보

제13장 임상시험 분석

제14장 세계의 폐암 치료제 시장 : SWOT 분석

제15장 경쟁 구도

• AstraZeneca Plc
• Boehringer Ingelheim International GmbH.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co
• Pfizer Inc.
• Allergan Inc.
• Teva Pharmaceutical Industries Ltd.
• Abbvie, Inc.

제16장 전략적 제안

제17장 기업 소개와 면책사항

SHW

영문 목차

영문목차

Global Lung Cancer Therapeutics Market was valued at USD 25.43 billion in 2024 and is expected to reach USD 40.55 billion by 2030 with a CAGR of 9.62% during the forecast period. The global lung cancer therapeutics market is witnessing robust growth due to increasing awareness, early diagnosis, and advancements in targeted and immunotherapies. Lung cancer remains one of the most commonly diagnosed and deadliest forms of cancer worldwide, making effective treatment a high priority for healthcare systems. The rising prevalence of smoking, exposure to environmental pollutants, and aging populations are key drivers fueling demand for innovative treatment options. Non-small cell lung cancer is the most prevalent type and has seen the greatest therapeutic advancements, especially through targeted therapies that focus on genetic mutations. Immunotherapies are also gaining momentum, offering hope by helping the body's immune system recognize and attack cancer cells more effectively. These treatment modalities are reshaping the market landscape and improving patient survival rates. For instance, The World Health Organization (WHO) recognizes tobacco as a significant health risk, causing over 8 million deaths each year, especially in low- and middle-income countries. WHO supports actions like smoke-free policies, advertising restrictions, and tax increases to curb tobacco use and encourage smoking cessation.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 25.43 Billion
Market Size 2030	USD 40.55 Billion
CAGR 2025-2030	9.62%
Fastest Growing Segment	Immunotherapy
Largest Market	North America

Key Market Drivers

Rising Incidence of Lung Cancer

The rising incidence of lung cancer is one of the most significant drivers propelling the global lung cancer therapeutics market. For instance, the growing prevalence of various cancer types, with lung cancer being one of the most common, has led to an increasing demand for lung cancer therapeutics. Rising incidences of lung cancer across all demographics and age groups contribute to this demand. The American Cancer Society (ACS) reports that approximately 13% of all new cancer diagnoses are lung cancers. Lung cancer continues to be one of the most frequently diagnosed cancers worldwide and remains a leading cause of cancer-related deaths. This growing burden is closely linked to widespread tobacco use, which remains the most common risk factor, particularly in low- and middle-income countries where smoking rates are still high. The exposure to secondhand smoke, environmental pollutants, occupational carcinogens like asbestos, and increasing levels of urban air pollution have contributed to a broader and more diverse at-risk population.

The surge in lung cancer cases has heightened the need for timely diagnosis and effective treatment, prompting healthcare systems to invest more in therapeutics. This has led to significant market expansion, particularly in areas focused on advanced treatments like targeted therapies and immunotherapies. As more patients are diagnosed at earlier stages due to improved screening programs and public awareness initiatives, the opportunity for therapeutic intervention increases, further driving demand for innovative drug development.

The changing lifestyle patterns, increasing life expectancy, and a growing elderly population are contributing to a higher number of lung cancer diagnoses globally. The disease's high mortality rate has also intensified efforts from pharmaceutical companies and research organizations to accelerate clinical trials and regulatory approvals for novel therapies. The global response to this growing health crisis is reflected in rising healthcare expenditures and policy reforms aimed at improving cancer care access.

Key Market Challenges

High Treatment Costs

High treatment costs are one of the most significant challenges facing the global lung cancer therapeutics market. While advancements in targeted therapies and immunotherapies have revolutionized the treatment landscape, these therapies come with high price tags. For instance, newer treatments that target specific genetic mutations, such as EGFR inhibitors or immune checkpoint inhibitors, can cost patients tens of thousands of dollars per year. This makes them financially inaccessible for a large portion of the global patient population, especially in low- and middle-income countries where healthcare systems may already be strained.

The high cost of these treatments is often a barrier for patients who do not have sufficient insurance coverage or financial support. In many regions, the lack of universal healthcare coverage means that out-of-pocket expenses for patients are significant. This situation can lead to delayed treatment or even treatment abandonment, resulting in poorer outcomes.For those who do access these therapies, long-term costs can be unsustainable, as many lung cancer therapies require continuous use.

Pharmaceutical companies argue that the high costs are necessary to recoup the considerable investments made in research, development, and clinical trials. However, the pricing of cancer therapies has sparked widespread debate, with calls for more affordable pricing models or reimbursement strategies to ensure equitable access to these life-saving treatments.

Ultimately, the high treatment costs create a divide between those who can afford cutting-edge therapies and those who cannot, limiting the global reach of these innovative treatments and hindering efforts to reduce lung cancer mortality rates worldwide.

Key Market Trends

Shift Toward Personalized Medicine

The shift toward personalized medicine is one of the most significant trends in the global lung cancer therapeutics market, marking a transformative approach to treatment that aims to tailor therapies to individual patients based on their genetic, molecular, and environmental profiles. This paradigm shift is reshaping how lung cancer is diagnosed, treated, and managed, moving away from a one-size-fits-all approach to more targeted, effective, and less invasive therapies.

Personalized medicine in lung cancer relies heavily on identifying specific genetic mutations, biomarkers, and molecular characteristics of both the cancer cells and the patient. For example, targeted therapies are now developed to treat non-small cell lung cancer (NSCLC) based on mutations such as EGFR, ALK, ROS1, and BRAF. These therapies can directly target the molecular drivers of cancer growth, resulting in more effective treatments with fewer side effects than traditional chemotherapy. The success of targeted therapies in improving survival rates has demonstrated the value of personalized approaches and increased demand for genetic testing and biomarkers.

The growing field of immunotherapy, especially immune checkpoint inhibitors, has benefited from the personalized medicine trend. These therapies are often more effective in certain patients based on the expression of biomarkers like PD-L1. By identifying which patients are most likely to benefit from immunotherapy, healthcare providers can optimize treatment plans and avoid unnecessary therapies for those less likely to respond.

The expansion of personalized medicine has also spurred growth in companion diagnostics, which are essential for identifying the right patient populations for specific treatments. The availability of such diagnostics helps ensure that patients receive the most appropriate therapies based on their individual profiles, leading to better outcomes and a more efficient use of healthcare resources.

The shift toward personalized medicine is driving significant innovation in the lung cancer therapeutics market, making treatments more precise, effective, and patient-centered. As research advances, the integration of personalized approaches is expected to continue expanding, further improving survival rates and quality of life for lung cancer patients.

Key Market Players

• AstraZeneca Plc
• Boehringer Ingelheim International GmbH.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co
• Pfizer Inc.
• Allergan Inc.
• Teva Pharmaceutical Industries Ltd.
• Abbvie, Inc.

Report Scope:

In this report, the Global Lung Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Therapeutics Market, By Cancer Cell Type:

• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

Lung Cancer Therapeutics Market, By Treatment:

• Chemotherapy
• Radiation Therapy
• Immunotherapy
• Targeted Therapy
• Other Treatments

Lung Cancer Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Therapeutics Market.

Available Customizations:

Global Lung Cancer Therapeutics Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Lung Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC))
  • 5.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Cancer Cell Type
  • 5.3.2. By Treatment

6. North America Lung Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 6.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Cell Type
      • 6.3.1.2.2. By Treatment
  • 6.3.2. Canada Lung Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Cell Type
      • 6.3.2.2.2. By Treatment
  • 6.3.3. Mexico Lung Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Cell Type
      • 6.3.3.2.2. By Treatment

7. Europe Lung Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 7.2.2. By Treatment ( Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Lung Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Cell Type
      • 7.3.1.2.2. By Treatment
  • 7.3.2. Germany Lung Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Cell Type
      • 7.3.2.2.2. By Treatment
  • 7.3.3. United Kingdom Lung Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Cell Type
      • 7.3.3.2.2. By Treatment
  • 7.3.4. Italy Lung Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Cell Type
      • 7.3.4.2.2. By Treatment
  • 7.3.5. Spain Lung Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Cell Type
      • 7.3.5.2.2. By Treatment

8. Asia-Pacific Lung Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 8.2.2. By Treatment ( Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Cell Type
      • 8.3.1.2.2. By Treatment
  • 8.3.2. Japan Lung Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Cell Type
      • 8.3.2.2.2. By Treatment
  • 8.3.3. India Lung Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Cell Type
      • 8.3.3.2.2. By Treatment
  • 8.3.4. South Korea Lung Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Cell Type
      • 8.3.4.2.2. By Treatment
  • 8.3.5. Australia Lung Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Cell Type
      • 8.3.5.2.2. By Treatment

9. South America Lung Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 9.2.2. By Treatment ( Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Lung Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Cell Type
      • 9.3.1.2.2. By Treatment
  • 9.3.2. Argentina Lung Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Cell Type
      • 9.3.2.2.2. By Treatment
  • 9.3.3. Colombia Lung Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Cell Type
      • 9.3.3.2.2. By Treatment

10. Middle East and Africa Lung Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 10.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Lung Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Cell Type
      • 10.3.1.2.2. By Treatment
  • 10.3.2. Saudi Arabia Lung Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Cell Type
      • 10.3.2.2.2. By Treatment
  • 10.3.3. South Africa Lung Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Cell Type
      • 10.3.3.2.2. By Treatment

11. Market Dynamics

• 11.1. Drivers
  • 11.1.1. Increasing Prevalence of Lung Cancer.
  • 11.1.2. Rise in the number of Tobacco Smokers
  • 11.1.3. Rise in demand for Immunotherapy
• 11.2. Challenges
  • 11.2.1. High Cost of Cancer Treatment
  • 11.2.2. Side Effects of Drugs
  • 11.2.3. Lack of skilled workforce

12. Market Trends & Developments

• 12.1. Product Launches
• 12.2. Mergers & Acquisitions
• 12.3. Technological Advancements

13. Clinical Trial Analysis

14. Global Lung Cancer Therapeutics Market: SWOT Analysis

15. Competitive Landscape

• 15.1. AstraZeneca Plc
• 15.2. Boehringer Ingelheim International GmbH.
• 15.3. Bristol-Myers Squibb Company
• 15.4. Eli Lilly and Company
• 15.5. F. Hoffmann-La Roche Ltd.
• 15.6. Merck & Co
• 15.7. Pfizer Inc.
• 15.8. Allergan Inc.
• 15.9. Teva Pharmaceutical Industries Ltd.
• 15.10. Abbvie, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer

관련자료